BioPlus Competitors

Delisted . USA . 
Stock . BioPlus Acquisition Corp
BIOSDelisted Stock  USD 10.73  0.00  0.00%   
BioPlus Acquisition Corp competes with DP Cap, Oak Woods, Insight Acquisition, ClimateRock, and Swiftmerge Acquisition; as well as few others. The company conducts business under Capital Markets sector and is part of Financials industry. Analyzing BioPlus Acquisition competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of BioPlus Acquisition to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of BioPlus Acquisition competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
10.7310.7310.73
Details
Intrinsic
Valuation
LowRealHigh
9.069.0611.80
Details

BioPlus Acquisition Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between BioPlus Acquisition and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of BioPlus and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of BioPlus Acquisition Corp does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
OCAX
+ 0.78
OLIT
OAKUU
+ 0.74
OLIT
USCTW
+ 0.69
BLNGW
OAKUU
+ 0.67
OCAX
OAKUU
+ 0.51
DPCS
CCAIW
+ 0.43
CNDB
  
High negative correlations   
BLNGW
- 0.86
OLIT
BLNGW
- 0.79
OCAX
BLNGW
- 0.74
OAKUU
USCTW
- 0.71
OLIT
USCTW
- 0.64
OCAX
USCTW
- 0.57
OAKUU

Risk-Adjusted Indicators

There is a big difference between BioPlus Stock performing well and BioPlus Acquisition Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BioPlus Acquisition's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
CNDB  0.03 (0.01) 0.00 (1.61) 0.00 
 0.00 
 0.10 
(0.10)
 0.38 
OLIT  0.13  0.04 (0.17)(0.55) 0.00 
(0.44)
 0.67 
(0.19)
 1.74 
DPCS  0.61  0.18  0.02 (0.89) 0.75 
(1.71)
 0.70 
(0.55)
 17.65 
OCAX  0.31  0.02 (0.14)(0.21) 0.42 
(0.48)
 0.82 
(1.07)
 3.26 
OAKUU  0.37  0.05  0.00 (0.65) 0.00 
 0.00 
 1.44 
(0.87)
 8.58 
CCAIW  18.02  2.77  0.13  1.47  18.15 
(22.58)
 49.08 
(30.91)
 148.40 
BLNGW  40.03  12.03  0.23 (0.36) 30.14 
(77.77)
 146.00 
(66.67)
 495.20 
USCTW  20.79  0.85  0.05  0.25  21.55 
(37.71)
 66.00 
(43.02)
 140.84 
KWACW  52.43  20.09  0.45 (1.66) 29.03 
(93.04)
 161.33 
(62.22)
 749.43 
All Fundamental Data

BioPlus Acquisition Competitive Analysis

The better you understand BioPlus Acquisition competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, BioPlus Acquisition's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across BioPlus Acquisition's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BIOS CNDB OLIT DPCS OCAX OAKUU CCAIW BLNGW USCTW KWACW
 0.00 
 10.73 
BioPlus
 0.00 
 10.40 
Concord
 0.00 
 10.49 
Omnilit
 0.00 
 12.60 
DPCS
 0.45 
 11.10 
OCA
 1.14 
 11.50 
Oak
 22.64 
 0.09 
Cascadia
 0.00 
 0.0006 
Belong
 0.00 
 0.01 
TKB
 0.00 
 0.01 
Kingswood
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Not too volatile
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
OK
Very Weak
Insignificant
Very Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Dangerous
Dangerous
Dangerous
Very High
Dangerous
Dangerous
Dangerous
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Not Rated
Strong Sell
Not Rated
Hold
Not Rated
Not Rated
Not Rated
Not Rated
Current Ratio
2.96
6.65
3.27
14.06
0.02
N/A
N/A
N/A
N/A
N/A
Net Asset
238.32 M
42.73 M
14.27 M
44.72 M
42.29 M
61.2 M
152.39 M
52.32 M
23.53 M
118.83 M
EBITDA
(1.17 M)
(4.87 M)
(787.64 K)
3.79 M
(3.18 M)
N/A
(7.59 M)
(4.75 M)
(4.42 M)
N/A
Current Valuation
215.16 M
126.18 M
52.19 M
95.69 M
78.36 M
88.06 M
N/A
N/A
N/A
N/A
Price To Book
N/A
4.52
N/A
25.49
4.21
N/A
N/A
N/A
N/A
N/A
Retained Earnings
(14.78 M)
(14.49 M)
(265.62 K)
(13.34 M)
(14.16 M)
(636.35 K)
(5.38 M)
(6.18 M)
(8.96 M)
N/A
Current Asset
183.69 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.14
-0.001
N/A
0.029
-0.007
N/A
N/A
N/A
0.002
N/A
Number Of Employees
38
2
3
3
2
N/A
N/A
2
11
3
Shares Outstanding
19.37 M
12.57 M
5.35 M
7.25 M
3.3 M
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(691.47 K)
(2.68 M)
(644.47 K)
(536.66 K)
(511.72 K)
(650.77 K)
(858.57 K)
9.21 M
(862.99 K)
N/A
Total Debt
5 M
35 K
N/A
4.6 M
3.33 M
2.84 M
221.78 K
76.72 K
682.51 K
N/A
Return On Equity
N/A
N/A
N/A
N/A
N/A
0.0124
N/A
N/A
N/A
N/A
Z Score
24.97
N/A
-0.2
N/A
N/A
N/A
-0.22
-0.7
N/A
N/A
Return On Asset
-0.0072
-0.0152
-0.0061
-0.0269
-0.0546
-0.0249
N/A
N/A
-0.0211
N/A
Number Of Shares Shorted
1.64 K
7.07 K
1.29 K
416
8.11 K
1
4.34 K
12.35 K
1.44 K
N/A
Book Value Per Share
-0.86
-1.15
-0.18
-1.36
-2.27
7.75
0.006
0.006
-0.005
-0.47
Current Liabilities
152.76 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
238.32 M
42.73 M
14.27 M
44.72 M
42.29 M
61.2 M
152.39 M
52.32 M
23.53 M
118.83 M
Debt To Equity
7.23
8.59
N/A
5.5
4.71
N/A
N/A
3.2
N/A
N/A
Short Ratio
0.03
0.24
0.26
0.48
0.63
N/A
N/A
N/A
N/A
N/A
Target Price
20.0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
51.31
34.83
26.46
64.14
90.65
3.47
N/A
N/A
N/A
N/A
Market Capitalization
208.98 M
126.17 M
51.82 M
91.35 M
74.5 M
N/A
N/A
N/A
N/A
N/A
Price To Earning
-3.62
N/A
N/A
N/A
27.35
N/A
N/A
N/A
N/A
N/A
Price To Earnings To Growth
-7.93
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Net Income
2 M
(2 M)
847.62 K
3.79 M
(2.48 M)
1.31 M
6.89 M
2.99 M
2.59 M
N/A
Earnings Per Share
0.21
-0.09
-0.04
0.01
-0.28
N/A
N/A
N/A
N/A
N/A
Shares Owned By Insiders
48.69
N/A
N/A
N/A
N/A
0.3
N/A
N/A
N/A
N/A
Working Capital
21.89 K
(6.98 M)
143.63 K
(692.82 K)
(8.09 M)
(382.2 K)
(201.08 K)
(10.4 M)
(1.29 M)
N/A
Cash And Equivalents
294.69 K
541.12 K
190.01 K
1.19 M
178
N/A
N/A
25
N/A
N/A
Cash Per Share
0.01
0.01
0.01
0.04
N/A
N/A
N/A
N/A
N/A
N/A
Day Typical Price
10.71
10.41
10.49
12.6
11.08
11.49
0.0967
8.0E-4
0.011
0.0082
Accumulation Distribution
0.0047
0.0019
N/A
N/A
0.0045
0.0121
0.29
0.54
N/A
N/A
Market Facilitation Index
0.05
0.02
N/A
N/A
0.05
0.14
0.0349
7.0E-4
N/A
N/A
Daily Balance Of Power
N/A
N/A
0.0
0.0
1.0
0.9286
(0.71)
N/A
0.0
0.0
Period Momentum Indicator
N/A
N/A
N/A
N/A
0.05
0.13
(0.02)
N/A
N/A
N/A
Rate Of Daily Change
1.0
1.0
1.0
1.0
1.0
1.01
0.77
1.0
1.0
1.0
Day Median Price
10.71
10.41
10.49
12.6
11.08
11.48
0.1
0.001
0.011
0.0082
Price Action Indicator
0.025
(0.01)
N/A
N/A
0.05
0.085
(0.03)
(0.0003)
N/A
N/A
Coefficient Of Variation
548.91
(4,626)
643.79
1046.48
2146.72
1757.64
869.91
872.61
1855.69
569.13
Mean Deviation
0.1494
0.0345
0.1331
0.6143
0.3146
0.3736
18.02
40.03
20.79
52.43
Jensen Alpha
0.0208
(0.01)
0.0363
0.1821
0.0232
0.052
2.77
12.03
0.846
20.09
Total Risk Alpha
(0)
(0.02)
(0.01)
(0.12)
(0.07)
(0.10)
(1.07)
(3.21)
(3.01)
2.18
Sortino Ratio
(0.34)
N/A
(0.17)
0.0175
(0.14)
N/A
0.1306
0.2326
0.046
0.4499
Downside Variance
0.0705
N/A
0.2603
5.8
0.5574
N/A
492.2
1468.08
1020.98
1715.73
Standard Deviation
0.2132
0.0664
0.2565
1.79
0.5319
0.9501
26.32
78.9
29.65
106.79
Kurtosis
2.77
2.66
6.13
31.68
3.51
16.83
3.02
15.67
0.7135
27.07
Potential Upside
0.3795
0.0963
0.6718
0.6987
0.8212
1.44
49.08
146.0
66.0
161.33
Treynor Ratio
0.428
(1.61)
(0.55)
(0.89)
(0.21)
(0.65)
1.47
(0.36)
0.2539
(1.66)
Maximum Drawdown
1.13
0.3846
1.74
17.65
3.26
8.58
148.4
495.2
140.84
749.43
Variance
0.0455
0.0044
0.0658
3.19
0.2829
0.9027
692.93
6225.34
879.41
11404.69
Market Risk Adjusted Performance
0.438
(1.60)
(0.54)
(0.88)
(0.20)
(0.64)
1.48
(0.35)
0.2639
(1.65)
Risk Adjusted Performance
0.1134
(0.12)
0.0989
0.0788
0.0312
0.0454
0.0976
0.0975
0.0509
0.1442
Skewness
0.0145
(0.56)
0.8298
4.18
0.3855
(1.75)
1.08
3.64
0.6501
4.71
Semi Deviation
0.0
N/A
0.0
0.7516
0.4168
N/A
18.15
30.14
21.55
29.03
Information Ratio
(0.42)
(1.96)
(0.35)
0.0236
(0.20)
(0.08)
0.1101
0.113
0.0496
0.1745
Value At Risk
(0.28)
(0.1)
(0.19)
(0.55)
(1.07)
(0.87)
(30.91)
(66.67)
(43.02)
(62.22)
Expected Short fall
(0.21)
N/A
(0.44)
(1.71)
(0.48)
N/A
(22.58)
(77.77)
(37.71)
(93.04)
Downside Deviation
0.2655
N/A
0.5102
2.41
0.7466
N/A
22.19
38.32
31.95
41.42
Semi Variance
(0.01)
N/A
(0.02)
0.565
0.1737
N/A
329.5
908.41
464.47
842.56

BioPlus Acquisition Competition Performance Charts

Five steps to successful analysis of BioPlus Acquisition Competition

BioPlus Acquisition's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by BioPlus Acquisition Corp in relation to its competition. BioPlus Acquisition's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of BioPlus Acquisition in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact BioPlus Acquisition's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to BioPlus Acquisition Corp, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your BioPlus Acquisition position

In addition to having BioPlus Acquisition in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Latest Losers Thematic Idea Now

Latest Losers
Latest Losers Theme
Dynamically computed list of top equities currently sorted across major exchanges. The Latest Losers theme has 204 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Latest Losers Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Other Consideration for investing in BioPlus Stock

If you are still planning to invest in BioPlus Acquisition Corp check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the BioPlus Acquisition's history and understand the potential risks before investing.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Bonds Directory
Find actively traded corporate debentures issued by US companies
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY